Introduction Most breast cancer-related deaths arise from triple-negative breast cancer
(TNBC). Molecular heterogeneity, aggressiveness and the lack of effective therapies are …

Breast cancer is the most common malignancy and the second most common cause of
cancer-related mortality in women. Triple-negative breast cancers do not express estrogen …

One of the most common cancers that occur in females is breast cancer. Despite the
significant leaps and bounds that have been made in treatment of breast cancer, the disease …

The tumor extracellular matrix (ECM) critically regulates cancer progression and treatment
response. Expression of the basement membrane component collagen XVIII (ColXVIII) is …

Breast cancer has been confirmed to have lipid disorders in the tumour microenvironment.
Peroxisome proliferator-activated receptor alpha (PPARα) is a ligand-activated …

Breast cancer is a leading death cause in women globally. Since therapeutic products do
not yet approach the tumor tissue at adequate levels; therefore, nanoparticle-based …

Chemotherapy, targeted therapy, and immunotherapy are effective against most tumors, but
drug resistance remains a barrier to successful treatment. Lysine-specific demethylase 1 …

Triple-negative breast cancer (TNBC) is a subset of breast cancer with aggressive
characteristics and few therapeutic options. The lack of an appropriate therapeutic target is a …

Triple-negative breast cancer (TNBC) comprises lethal malignancies with limited treatment
options. Chimeric antigen receptor T (CAR-T) cell therapy is an effective immunotherapeutic …

Evidence has long suggested that epidermal growth factor receptor (EGFR) may play a
prominent role in triple-negative breast cancer (TNBC) pathogenesis, but clinical trials of …